Ozuriftamab vedotin
- Generic Name
- Ozuriftamab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2460400-11-5
- Unique Ingredient Identifier
- BPM6YN0KLI
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05271604
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Christiana Care Helen Graham Cancer Center, Newark, Delaware, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath